United Therapeutics Corporation Common Stock (UTHR)
Stock · NASDAQ · Health Care
$533.35as of 10/16/2026
Price chart
Active signals
UTHR Signal Track Record
How signals performed across all stocks →What UTHR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 40 | +3.1% | 60% | September 17, 2026 |
| Bollinger Band Breakout | 27 | -1.1% | 41% | September 30, 2026 |
| Bollinger Band Breakdown | 17 | -0.5% | 41% | September 24, 2026 |
| 200-Day Moving Average TouchActive now | 11 | -0.9% | 45% | August 18, 2026 |
| Any 20-session window (baseline) | +0.7% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About UTHR
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat p…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 1,400
- Website
- www.unither.com/
Fundamentals
- 1-day range
- $530.18$551.77
- Market cap
- $22.62B
- P/E (trailing)
- 17.78
- P/E (forward)
- 17.53
- EPS (trailing)
- $27.96
- Dividend yield
- —
- Beta
- 0.49
- Avg. volume
- 702.2K
How United Therapeutics Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 25, 2026 · via SEC EDGAR / Finnhub
Forecasts
14 analyst ratings
United Therapeutics Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- UTHRUnited Therapeutics Corporation Common Stock$533.12▼ 1.55%Market cap $22.62BP/E 17.78$409.07$609.35
- ROIVRoivant Sciences Ltd. Common Shares$33.53▼ 1.50%Market cap $25.38BP/E —$15.9$42.5
- VTRSViatris Inc. Common Stock$18.66▲ 2.41%Market cap $18.97BP/E —$9.73$18.43
- JAZZJazz Pharmaceuticals plc Common Stock (Ireland)$210.23▼ 1.95%Market cap $16.66BP/E 14.90$128.8$266.38
- INSMInsmed Incorporated Common Stock$96.27▼ 2.96%Market cap $28.73BP/E —$90.39$212.75
- ALNYAlnylam Pharmaceuticals Inc. Common Stock$231.83▼ 0.94%Market cap $28.92BP/E 37.17$197.81$495.55
- BBIOBridgeBio Pharma Inc. Common Stock$66.39▼ 1.10%Market cap $16.20BP/E —$52.75$93.42
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| UTHR United Therapeutics Corporation Common Stock | $22.62B | 17.78 | $533.12 | ▼ 1.55% | $409.07$609.35 |
| ROIV Roivant Sciences Ltd. Common Shares | $25.38B | — | $33.53 | ▼ 1.50% | $15.9$42.5 |
| VTRS Viatris Inc. Common Stock | $18.97B | — | $18.66 | ▲ 2.41% | $9.73$18.43 |
| JAZZ Jazz Pharmaceuticals plc Common Stock (Ireland) | $16.66B | 14.90 | $210.23 | ▼ 1.95% | $128.8$266.38 |
| INSM Insmed Incorporated Common Stock | $28.73B | — | $96.27 | ▼ 2.96% | $90.39$212.75 |
| ALNY Alnylam Pharmaceuticals Inc. Common Stock | $28.92B | 37.17 | $231.83 | ▼ 0.94% | $197.81$495.55 |
| BBIO BridgeBio Pharma Inc. Common Stock | $16.20B | — | $66.39 | ▼ 1.10% | $52.75$93.42 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Liquidia Settles Bitter Fight With United Therapeuticsbenzinga · 10/14/2026
- RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $708Benzinga · 10/8/2026
- 3 Reasons to Avoid UTHR and 1 Stock to Buy InsteadYahoo · 10/7/2026
- Morgan Stanley Maintains Equal-Weight on United Therapeutics, Raises Price Target to $566Benzinga · 10/7/2026
- Liquidia (LQDA) Could Be 74% Undervalued As Court Ruling Clouds YUTREPIA AccessYahoo · 10/7/2026
- Stocktwits Wall Street Wrap: Analysts Turn Bullish On Sweetgreen, Target And Airbnb – Liquidia And FICO Face DowngradesYahoo · 10/2/2026
- Liquidia Shares Tank On Patent Court Loss, Rivals May Just Be Getting StartedSeekingAlpha · 10/2/2026
- United Therapeutics Just Sent Liquidia Stock Lower After Patent BattleYahoo · 10/1/2026
- Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSetYahoo · 10/1/2026
Insider Activity
Insider Actions →- Martine A. Rothblatt · October 8, 2026 · Option Exercise9.5K @ $117.76
- Martine A. Rothblatt · October 8, 2026 · Sale40 @ $541.23
- Martine A. Rothblatt · October 8, 2026 · Sale424 @ $540.51
- Martine A. Rothblatt · October 8, 2026 · Sale1.1K @ $539.58
- Martine A. Rothblatt · October 8, 2026 · Sale605 @ $538.6
- Martine A. Rothblatt · October 8, 2026 · Sale1.0K @ $537.53
- Martine A. Rothblatt · October 8, 2026 · Sale824 @ $536.61
- Martine A. Rothblatt · October 8, 2026 · Sale480 @ $535.46
- Martine A. Rothblatt · October 8, 2026 · Sale920 @ $534.28
- Martine A. Rothblatt · October 8, 2026 · Sale800 @ $533.36
- Martine A. Rothblatt · October 8, 2026 · Sale600 @ $532.07
- Martine A. Rothblatt · October 8, 2026 · Sale1.1K @ $531.07
- Martine A. Rothblatt · October 8, 2026 · Sale199 @ $530.13
- Martine A. Rothblatt · October 8, 2026 · Sale200 @ $525.5
- Martine A. Rothblatt · October 8, 2026 · Sale273 @ $527.57
Institutional Ownership
March 31, 2026
- Total shares held
- 42.45M
- Total value held
- $23.63B
- Institutional holders
- 838
- Unknown5.40M
- Unknown3.01M
- Unknown2.26M
- Unknown1.96M
- Unknown1.84M
- Unknown1.79M
- Unknown1.23M
- Unknown1.15M
- Unknown866.9K
- Unknown862.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
United Therapeutics Settles Litigation, Market Reassesses Valuation
United Therapeutics has settled a litigation that impacts its pulmonary hypertension business. The settlement resets competition in that market and has led analysts to question whether the stock is undervalued. The move may prompt a reassessment of the company’s value by investors.
United Therapeutics Settles Litigation, Market Reassesses Valuation. United Therapeutics has settled a litigation that impacts its pulmonary hypertension business. The settlement resets competition in that market and has led analysts to question whether the stock is undervalued. The move may prompt a reassessment of the company’s value by investors.